Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Nanobiotix (NBTX) Receivables - Net (2019 - 2025)

Nanobiotix has reported Receivables - Net over the past 6 years, most recently at $2.5 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 22.44% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, down 22.44%, while the annual FY2025 figure was $2.5 million, 22.44% down from the prior year.
  • Receivables - Net for Q4 2025 was $2.5 million at Nanobiotix, up from $2.1 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $3.4 million in Q2 2024 and troughed at $103045.0 in Q4 2022.
  • A 4-year average of $1.7 million and a median of $1.6 million in 2023 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: soared 844.95% in 2023 and later tumbled 38.13% in 2025.
  • Year by year, Receivables - Net stood at $103045.0 in 2022, then soared by 844.95% to $973725.6 in 2023, then skyrocketed by 229.23% to $3.2 million in 2024, then fell by 22.44% to $2.5 million in 2025.
  • Business Quant data shows Receivables - Net for NBTX at $2.5 million in Q4 2025, $2.1 million in Q2 2025, and $3.2 million in Q4 2024.